ZYNLONTA® (loncastuximab tesirine-lpyl) – Reinitiation of Therapy after a Missed Cycle

Overview

- ZYNLONTA is an intravenous (IV) infusion which should be administered over 30 minutes on Day 1 of each cycle (every 3 weeks). Administer IV infusion as follows:[1]
    - 0.15 mg/kg every 3 weeks for 2 cycles
    - 0.075 mg/kg every 3 weeks for subsequent cycles
- In the event a patient is unable to receive their scheduled cycle and misses a dose for reasons unrelated to toxicity from ZYNLONTA treatment, they may resume treatment whenever possible. There is no guidance to make up for missed doses.[2]
- If there is a delay in infusion for reasons unrelated to toxicity, subsequent infusions may be given 3 weeks from the last infusion. Do not shorten the time between infusion to compensate for delay.[2]
- ADC Therapeutics does not recommend dosage or administration of ZYNLONTA outside of what is recommended in the Prescribing Information. If there is an interruption in therapy for your patient for reasons unrelated to toxicity or if a dose is missed, please defer to your clinical judgment.
    - See the **Relevant Prescribing Information** section for further information regarding dosage, administration, dose modifications, and dose discontinuations of ZYNLONTA due to drug toxicity.

Literature Search

- A PubMed biomedical literature search conducted on April 1, 2025, yielded no relevant data regarding reinitiation of therapy after a missed cycle of ZYNLONTA.

Relevant Prescribing Information

Section 2: Dosage and Administration[1]

2.1: Recommended Dosage

- ZYNLONTA as an intravenous infusion administered over 30 minutes on Day 1 of each cycle (every 3 weeks). Administer intravenous infusion as follows:
    - 0.15 mg/kg every 3 weeks for 2 cycles
    - 0.075 mg/kg every 3 weeks for subsequent cycles

2.3: Dosage Modifications and Delays[1]

Adverse Reactions	Severity[a]	Dosage Modification
Hematologic Adverse Reactions		
Neutropenia *[see Warnings and Precautions (5.2)]*	Absolute neturophil count less than 1 x 10^9/L	Withhold ZYNLONTA until neturophil counts returns to 1 x 10^9/L or higher

Adverse Reactions	Severity[a]	Dosage Modification
Hematologic Adverse Reactions		
Thrombocytopenia *[see Warnings and Precautions (5.2)]*	Platelet count less than 50,000/mcL	Withhold ZYNLONTA until platelet count returns to 50,000/mcL or higher
Nonhematologic Adverse Reactions		
Edema or Effusion [*see Warnings and Precautions (5.1)*]	Grade 2[a] or higher	Withhold ZYNLONTA until the toxicity resolves to Grade 1 or less
Other Adverse Reactions [*see Warnings and Precautions (5.3), (5.4), Adverse Reactions (6.1)]*	Grade 3[a] or higher	Withold ZYNLONTA until the toxicity resolves to Grade 1 or less

a National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0

- If dosing is delayed by more than 3 weeks due to toxicity related to ZYNLONTA, reduce subsequent doses by 50%. If toxicity reoccurs following dose reduction, consider discontinuation.
- If toxicity requires dose reduction following the second dose of 0.15 mg/kg (Cycle 2), the patient should receive the dose of 0.075 mg/kg for Cycle 3.

Section 6: Adverse Reactions[1]

6.1: Clinical Trials Experience

- Permanent treatment discontinuation due to an adverse reaction of ZYNLONTA occurred in 19% of patients. Adverse reactions resulting in permanent discontinuation of ZYNLONTA in ≥2% were gamma-glutamyltransferase increased, edema, and effusion.
- Dose reductions due to an adverse reaction of ZYNLONTA occurred in 8% of patients. Adverse reactions resulting in dose reduction of ZYNLONTA in ≥4% was gamma-glutamyltransferase increased.
- Dosage interruptions due to an adverse reaction occurred in 49% of patients receiving ZYNLONTA. Adverse reactions leading to interruption of ZYNLONTA in ≥5% were gamma-glutamyltransferase increased, neutropenia, thrombocytopenia, and edema.

References

[1] ZYNLONTA® (loncastuximab tesirine-lpyl) FDA-approved Prescribing Information. October 2022.
[2] Data on File. Memo. ADC Therapeutics.

ADC Therapeutics encourages all health care professionals to report any adverse events and product quality complaints to medical information at 855-690-0340. Please consult the ZYNLONTA Prescribing Information.